Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.
about
Role of Inflammation in Muscle Homeostasis and MyogenesisDepletion of white adipose tissue in cancer cachexia syndrome is associated with inflammatory signaling and disrupted circadian regulationSTAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia.Cancer cachexia: a therapeutic approach.Metabolic and morphological alterations induced by proteolysis-inducing factor from Walker tumour-bearing rats in C2C12 myotubes.Inflammation based regulation of cancer cachexiaCancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling.Cytokines and cancer anorexia cachexia syndrome.Optimal management of cancer anorexia-cachexia syndrome.Nutrition in head and neck cancer patientsIbuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patientsRel A/p65 is required for cytokine-induced myotube atrophy.JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.Pathogenesis of muscle wasting in cancer cachexia: targeted anabolic and anticatabolic therapies.Elevated tumour interleukin-1beta is associated with systemic inflammation: A marker of reduced survival in gastro-oesophageal cancer.Emerging drugs for cancer cachexia.Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice.Purine receptor antagonist modulates serology and affective behaviors in lupus-prone mice: evidence of autoimmune-induced pain?Anti-cytokine strategies for the treatment of cancer-related anorexia and cachexia.Role of interleukin 1 beta in esophageal squamous cell carcinoma.Suramab, a novel antiangiogenic agent, reduces tumor growth and corneal neovascularization.Cancer cachexia is regulated by selective targeting of skeletal muscle gene productsModulation of interleukin-6/interleukin-6 receptor cytokine loop in the treatment of multiple myeloma.Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines.Suramin treatment suppresses induction of experimental autoimmune uveoretinitis (EAU) in rodents.Metabolic Changes During Cancer Cachexia Pathogenesis.Increased gut permeability in cancer cachexia: mechanisms and clinical relevance.eIF4A inhibition prevents the onset of cytokine-induced muscle wasting by blocking the STAT3 and iNOS pathways.
P2860
Q26778322-6758AF6A-A800-41BC-AD79-A54A4BEDA7FDQ27312755-4EAD8550-2821-49D8-B8C9-1C92EB9DF31CQ31028277-96383922-64F5-40FF-A908-0820D476082BQ31791590-BE2CD6DB-F1A8-4AC5-A66E-454F139DDF20Q33316844-DF985240-ACCA-47FE-A073-11F62BA31D5FQ33615916-5056DB2B-2705-4014-A377-17C297F8A4FEQ33700636-6E855C39-03FB-4616-9EE4-6F8A4F9828FFQ34011011-05E740F2-937D-4619-80C6-FE842AF38E67Q34417908-3041769D-1423-4299-82CA-3689CD1BBAE7Q35882986-B6353530-FE43-4F78-83DE-ADC4EAE81F06Q36081975-1CA225E5-93D2-4067-9034-532F8FC4AF46Q36114658-62AAFF4B-BD69-4D29-A12D-C82C66F08F3EQ36176015-70E3B7D5-1C67-421A-821C-2913C748E782Q36202135-8CAE2933-21A6-4ACE-A4FE-366FF448E8A1Q36612480-93E5C9EE-D25B-4884-8D20-30736A7B8D8AQ36989913-2490A3FE-23BF-4293-8F3E-33061469390AQ37351404-CC97EB24-F218-484E-9ADE-5A27CE3BD369Q37440064-06BF5D26-6304-4305-AA75-B69CE2A59B91Q37769250-8D00A872-7BCF-4420-AC85-F064B04F83E0Q39474854-D28E76F5-2448-4B11-A0FA-3B82B9F992D1Q39951636-9AF29DFE-77C7-443B-8B89-FCD21602D7ACQ40529830-ADBBF2DD-0C6A-49EF-8537-1106DB0CE779Q40875040-3E9E6B8C-E91D-4F05-8763-6BBD6C6B4D3BQ41208928-41ACE892-37EA-4065-BFC0-BEB2EA5778D9Q41287896-8A4AD2E8-6573-4E92-A369-C45D60216309Q49544329-CD21E365-6B67-4E64-B520-1344548A714FQ53688957-5F0FE283-12D3-4F37-AD73-74330D06C071Q54959711-D7EAA3F6-BBB3-49B1-953C-13E1F69DA2FE
P2860
Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.
description
1993 nî lūn-bûn
@nan
1993 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Suramin interferes with interl ...... ental cancer cachexia in vivo.
@ast
Suramin interferes with interl ...... ental cancer cachexia in vivo.
@en
type
label
Suramin interferes with interl ...... ental cancer cachexia in vivo.
@ast
Suramin interferes with interl ...... ental cancer cachexia in vivo.
@en
prefLabel
Suramin interferes with interl ...... ental cancer cachexia in vivo.
@ast
Suramin interferes with interl ...... ental cancer cachexia in vivo.
@en
P2093
P2860
P356
P1476
Suramin interferes with interl ...... ental cancer cachexia in vivo.
@en
P2093
D'Alessandro F
Strassmann G
P2860
P304
P356
10.1172/JCI116816
P407
P577
1993-11-01T00:00:00Z